Eikon Therapeutics joined the Unicorn Club on January 6, 2022, after raising a $518 million Series B funding round led by T. Rowe Price, CPP Investments, and EcoR1 Capital, valuing the company at $3.1 billion. Headquartered in Hayward, California, United States, Eikon develops advanced protein-tracking and measurement technologies to accelerate the discovery of new drugs. With $1.16 billion in total funding and a growing team of 11–50 employees (as of July 2024), Eikon combines super-resolution microscopy, computation, and engineering to transform how scientists study protein behavior in live cells.
Keep reading to explore Eikon’s breakthrough platform, funding journey, and what’s next for this life sciences innovator.
What Is Eikon and What Does It Do?
Founded in 2019, Eikon Therapeutics is a biotechnology and life sciences company specializing in protein tracking and measurement to accelerate the discovery and development of therapeutics. Its proprietary live-cell super-resolution microscopy platform enables scientists to observe the movement and interactions of individual proteins within living cells in real-time, a capability that helps identify drug targets and optimize molecules for greater efficacy.
Eikon’s multidisciplinary approach integrates biology, physics, engineering, and data science, enabling researchers to visualize protein dynamics with unprecedented precision. The company’s platform combines optical microscopy, AI-driven computation, and molecular biology, creating a robust environment for high-throughput screening and predictive modeling in oncology, immunology, and neurodegenerative diseases.
By bridging the gap between live-cell imaging and drug development, Eikon aims to shorten discovery timelines, improve target validation accuracy, and unlock new insights into disease mechanisms.
How Much Funding Has Eikon Raised?
- Series B
- Amount Raised: $518M
- Date: January 6, 2022
- Lead Investors: T. Rowe Price, CPP Investments, EcoR1 Capital
- Motivation: To scale R&D capabilities, expand lab operations, and advance its protein-mapping platform for large-scale therapeutic discovery.
- Series D
- Amount Raised: $351M
- Date: February 14, 2025
- Lead Investors: Not disclosed (participation from existing and new strategic investors)
- Motivation: To accelerate clinical-stage development, invest in automation, and expand into oncology and immunology research verticals.
Total Funding Raised: $1.16B
Latest Funding Date: February 14, 2025
Current Valuation: $3.1B
Employee Count: 11–50 (as of July 1, 2024)
Key Investors
- T. Rowe Price
- Details: Global asset management firm with strong investments in life sciences, healthcare innovation, and biotechnology startups.
- Investment Focus Areas: Therapeutics, drug discovery platforms, and computational biology.
- EcoR1 Capital
- Details: Biotechnology-focused investment firm supporting companies developing cutting-edge drug discovery technologies.
- Investment Focus Areas: Oncology, immunology, molecular biology, and genomic research.
- CPP Investments
- Details: Global investment manager for the Canada Pension Plan; a significant investor in biotechnology and health technology firms.
- Investment Focus Areas: Long-term biotech innovation, healthcare infrastructure, and life sciences ventures.
Where Is Eikon’s Headquarters?
Eikon Therapeutics is headquartered in Hayward, California, United States, part of the San Francisco Bay Area’s biotechnology corridor. This strategic location enables access to top-tier research talent, venture capital firms, and partnerships with nearby universities and pharmaceutical companies, driving advancements in drug discovery.
What’s Next for Eikon?
Following its $351 million Series D funding round and a valuation of $3.1 billion, Eikon is entering a new phase of growth, focusing on scaling its therapeutic discovery platform and advancing AI-driven research on protein dynamics. The company aims to move several drug candidates toward preclinical and clinical development, leveraging automation and computational modeling to enhance predictive accuracy.
Future goals include expanding partnerships with major pharmaceutical firms, increasing global R&D capacity, and further developing its live-cell imaging technologies for broader therapeutic applications, from oncology to rare diseases. Eikon’s blend of engineering precision and biological insight positions it as one of the most promising players in next-generation drug discovery.
Get Investor & Funding Insights with TexAu
TexAu provides verified investor and funding data for companies like Eikon Therapeutics. Track biotechnology funding rounds, identify leading investors, and discover growth opportunities in life sciences innovation.
Sign up for Free on TexAu and access deeper insights to guide your next strategic move.
